CTOR Citius Oncology, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CTOR matters now
Citius Oncology, Inc. (CTOR) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.69 with -4.20% on the session and $64.3M in market capitalization; recent performance reads 1-month -19.14% and YTD -33.03%.
The latest financial table shown here is Q2 2026, with revenue of $1.7M, net income of $-26.6M, and EPS of $-0.27. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -27.1%.
The latest indexable market news headline is "Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.90
P/S
11.10
EV/EBITDA
-1.54
DCF Value
$0.11
FCF Yield
-27.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.1%
Operating Margin
-775.6%
Net Margin
-757.6%
ROE
-99.5%
ROA
-42.2%
ROIC
-103.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.7M | $-26.6M | $-0.27 |
| Q1 2026 | $3.9M | $-5.5M | $-0.06 |
| Q4 2025 | $0.00 | $-5.0M | $-0.06 |
| FY 2025 | $0.00 | $-24.8M | $-0.34 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
3.42
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.